clinical trial · NCT05498428
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Janssen Research & Development, LLC·phase2·recruiting·n = 520
Carcinoma, Non-small-Cell LungAmivantamabLazertinibCarboplatinPemetrexedDirect Oral Anticoagulant (DOAC)Low Molecular Weight Heparin (LMWH)
brief summary
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).
started
Nov 11, 2022
primary completion
Aug 17, 2027
completion
Aug 18, 2028
last updated
Jul 6, 2026
official title
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol